By VETTAPHARMA reporter – Derek Roche: Amgen reported that it will present new clinical and real-world evidence across its rare autoimmune and inflammatory disease portfolio at the European Congress of Rheumatology (EULAR) 2026, taking place June 3–6 in London.
The presentations will feature data for UPLIZNA® (inebilizumab) in immunoglobulin G4-related disease (IgG4-RD) and TAVNEOS® (avacopan) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Among the featured presentations are new analyses from the Phase 3 MITIGATE study of UPLIZNA in IgG4-RD. According to Amgen, the analyses are intended to provide additional insights into disease biology while further characterizing the therapy’s efficacy and long-term safety profile in patients with the rare fibroinflammatory disease.
The MITIGATE trial evaluated UPLIZNA in adults with IgG4-RD, a chronic immune-mediated condition that can affect multiple organs and lead to irreversible tissue damage. The EULAR presentations are expected to include biomarker findings and long-term outcome analyses designed to improve understanding of treatment response and disease mechanisms.
Amgen also plans to present new real-world evidence for TAVNEOS in patients with ANCA-associated vasculitis. The analyses will examine treatment outcomes in clinical practice and include data related to corticosteroid use, an important consideration in managing the chronic autoimmune disease.
IgG4-RD and ANCA-associated vasculitis are rare immune-mediated disorders associated with significant morbidity and organ damage if not adequately controlled. Improved understanding of treatment outcomes may help clinicians optimize management strategies and support earlier intervention in affected patients.
For patients, the upcoming presentations may provide additional evidence regarding long-term disease control, safety, and treatment burden reduction. Data exploring steroid-sparing approaches in ANCA-associated vasculitis may be particularly relevant given the known adverse effects associated with prolonged corticosteroid exposure.
Commercially, the EULAR program highlights Amgen’s continued investment in rare immunology following the integration of Horizon Therapeutics. The planned presentations are expected to further expand the clinical evidence base supporting UPLIZNA and TAVNEOS across rare autoimmune diseases.
Quick FAQs
What Is the Drug/Product/Asset?
UPLIZNA (inebilizumab) is a CD19-targeting B-cell-depleting therapy being evaluated in immunoglobulin G4-related disease. TAVNEOS (avacopan) is a complement 5a receptor inhibitor used in ANCA-associated vasculitis.
What Happened?
Amgen reported that it will present new clinical and real-world evidence for UPLIZNA and TAVNEOS at EULAR 2026.
What Is the Study/Trial?
The featured clinical study is the Phase 3 MITIGATE trial evaluating UPLIZNA in patients with IgG4-related disease. Additional real-world analyses involving TAVNEOS in ANCA-associated vasculitis will also be presented.
What Is the Disease Condition?
IgG4-related disease is a chronic fibroinflammatory immune-mediated disorder that can affect multiple organs. ANCA-associated vasculitis is a rare autoimmune disease characterized by inflammation of small blood vessels that can result in serious organ damage.
What Were the Key Results?
The source announcement did not disclose detailed efficacy or safety results. Amgen stated that it will present new analyses from the Phase 3 MITIGATE study and new real-world evidence for TAVNEOS at EULAR 2026.
Why Is This Important?
The upcoming presentations may provide additional evidence regarding long-term treatment outcomes, disease biology, and real-world use of therapies for rare autoimmune diseases. Strategically, the data contribute to Amgen’s expanding rare immunology portfolio.
